~~<i id='93F129AB21'><strike id='93F129AB21'><tt id='93F129AB21'><pre id='93F129AB21'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

explore

author：entertainment 2025-09-29 00:39:10 - browse：5

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Maker of FluMist seeks to allow at

focus

Wikipedia

leisure time

entertainment

focus

Wikipedia

AdobePresidentBidenorderedthenation’sleadinghealthagenciesonMondaytodevelopaplanforregulatingartific

WSS

Data don't support strong claims for Covid

Illumina board agrees to spin off Grail, as divestment plans proceed

Medicare Advantage's lean provider networks lead CMS complaints

Emergency medicine has repudiated 'excited delirium.' Now what?

Readout Newsletter: What happened with Sarepta's Duchenne data

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

knowledge

explore

focus

At least 13 dead in Texas as scorching temps continue

The FDA weighs the risks of candy

Sports medicine is finally prioritizing gender equality

Eli Lilly to pay $200M for Beam’s stake in gene

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Biden's order seeks to regulate AI risk without stifling innovation

Virginia high school admissions case could be legal follow

Cassava reveals details — and problems — with Alzheimer's study

Medicare proposal to cover medical devices draws a mixed reaction

Structure Therapeutics oral GLP

Wikipedia

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Emergency medicine has repudiated 'excited delirium.' Now what?

Senate panel to vote on hospitals, PBMs, prisoner care

Illumina board agrees to spin off Grail, as divestment plans proceed

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Illumina board agrees to spin off Grail, as divestment plans proceed

leisure time

entertainment

focus

Wikipedia